Metastatic MHC class I-negative mouse cells derived by transformation with human papillomavirus type 16

British Journal of Cancer

Volumn 84, Issue 3, 2001, Pages 374-380

  Svmahel, M ^a   Sobotkov, E ^a   Buben'k, J ^b   Sv'mov, J ^b   Zvk, R ^a   Ludv'kov, V ^a   Hjkov, R ^b   Kovarv'k, J ^d   Jel'nek, F ^a   Povysvil, C ^c   Marinov, J ^a   Vonka, V ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

Cell transformation; DNA vaccine; E6 E7 oncogenes; H ras; Human papillomavirus; Tumour cell vaccine

Indexed keywords

DNA VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL CELL; ARTICLE; CELL SURVIVAL; EPITHELIUM CELL; GENE ACTIVATION; GENETIC TRANSFECTION; HIGH RISK POPULATION; HUMORAL IMMUNITY; MALIGNANT TRANSFORMATION; METASTASIS; MOUSE; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TARGET CELL; VIRUS INFECTION; WART VIRUS;

ANIMALS; CELL LINE; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, VIRAL; DNA, RECOMBINANT; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KERATINS; MALE; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PLASMIDS; RAS PROTEINS; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 17744385511     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1615     Document Type: Article

References (36)

1. Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines
2. A series of 14 new monoclonal antibodies to keratins: Characterization and value in diagnostic histopathology
3. Effects of tissue fixation conditions and protease pretreatment on immunohistochemical performance of a large series of new anti-keratin monoclonal antibodies: Value in oncopathology
4. A general method for isolation of high molecular weight DNA from eukaryotes
5. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective
6. IL-2 as adjuvant for vaccination with cells malignantly converted by HPV 16 or 3-MC
7. Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16
8. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen
9. Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16
10. A reagent for the single-step simultaneous isolation of RNA. DNA and proteins from cell and tissue samples
11. A new dominant hybrid selective marker for higher eukaryotic cells
12. Evaluation of multiple biological parameters in cervical carcinoma: High macrophage infiltration in HPV-associated tumours
13. Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours
14. The disruption of cell cycle checkpoints by papillomavirus oncoproteins contributes to anogenital neoplasia
15. The central role of CD4(+) T cells in the antitumor immune response
16. Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine
17. Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression
18. Properties of Syrian hamster cells transformed by human papillomavirus type 16
19. Growth of SV 40, adeno 7 and SV 40-adeno 7 viruses in monkey and human cells at 29 degrees and 37 degrees C
20. Determination of vires-specific antigens in extracts from herpes simplex virus-infected cells by a 51Cr release inhibition test
21. Novel monoclonal antibodies defining epitope of human cytokeratin 18 molecule
22. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen
23. The expression levels of the human papillomavirus type 16 E7 correlate with its transforming potential
24. HPV vaccine treatment trials proliferate, diversify
25. HPV vaccines for cervical cancer move toward clinic, encounter social issues
26. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma
27. Estimates of the worldwide incidence of eighteen major cancers in 1985
28. Isolation of a transforming sequence from a human bladder carcinoma cell line
29. DNA vaccine against oncogenic hamster cells transformed by HPV 16 E6/E7 oncogenes and the activated ras oncogene
30. Cross-reactivity of murine and hamster IL-2 mitogenic signal
31. Transforming activity of the E6 gene of HPV-11gt in NIH 3T3 and REF 52 cells: Correlation with the level of E6 transcription
32. Immunotherapeutic strategies for cervical squamous carcinoma
33. Human papillomavirus vaccines
34. Induction of anti-tumour immunity by suicide-gene-modified HPV-16-transformed hamster cells
35. The E7 open reading frame of human papillomavirus type 16 encodes a transforming gene
36. Viruses in human tumors - Reminiscences and perspectives